245 First Street - 18th Floor
Fax: 617- 444-8405
About GENFIT CORP.Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.
Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
183 articles with GENFIT CORP.
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
GENFIT informs its shareholders of certain participation and organization procedures for the ordinary and extraordinary general meeting of June 15, 2021 in accordance with decree n°2021-255 of March 9, 2021, extending the application of measures of ordinance n°2020-321 of March 25, 2020 and its application decree n°2020-418 of April 10, 2020 which was extended until July 31, 2021 by the decree n°2021-255 of March 9, 2021.
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced its cash position as of March 31, 2021 and revenues for the first three months of 2021.
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced a refocus of its R&D on acute on chronic liver failure and cholestatic diseases.
GENFIT announced that it published in the May 10, 2021 French legal announcements bulletin n°56 its convening notice that the Combined Shareholders Meeting will be held on June 15, 2021, at 2:30pm, at the Company’s headquarters, located at Parc Eurasanté, 885 avenue Eugène Avinée in Loos, France.
GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFIT’s NIS4™ Technology to Identify Patients with At-Risk NASH
Lille, France; Cambridge, MA;May 3, 2021 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced the launch of NASHnext®, a novel, noninvasive diagnostic test for nonalcoholic steatohepatitis.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
1/29/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
10/1/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and business practices.
8/6/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
7/27/2020It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Following negative interim data from its experimental treatment for non-alcoholic steatohepatitis (NASH) and fibrosis, France’s GENFIT will discontinue the Phase III RESOLVE-IT study of elafibranor in this indication.
7/10/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
5/18/2020Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
5/14/2020Biopharma and life sciences companies from across the globe provide updates on their pipeline and business.
They expect to share the complete findings with regulators in the upcoming months and make a final decision on whether to continue the clinical trial.
4/2/2020Biopharma companies from across the globe provide updates on their pipelines and business practices.
GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH
Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data
11/18/2019It was a busy week for clinical trial announcements. Here’s a look.
GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces its first half 2019 financial results.